NCT04161417

Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Status unknown NA Last updated 8 February 2024

What this trial tests

NA trial testing Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling in Neoplasms Pancreatic in 2,500 participants. Status unknown.

Timeline

28 November 2017

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Judith Dixon-Hughes
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	2,500
Start date	28 November 2017
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	33 locations across United Kingdom

Drugs / interventions tested

• Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling

Conditions studied

• Neoplasms Pancreatic — all drugs for Neoplasms Pancreatic →

Sponsor

Judith Dixon-Hughes — full company profile →

Who can join

16 and older, any sex, with Neoplasms Pancreatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development. Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.
   Menezes S, Okail MH, Jalil SMA, Kocher HM, et al · · 2022 · cited 51× · PMID 35533046 · DOI 10.1002/path.5926
2. The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer.
   Group Young Researchers In Inflammatory Carcinogenesis, Wandmacher AM, Mehdorn AS, Sebens S. · · 2021 · cited 27× · PMID 34638420 · DOI 10.3390/cancers13194932
3. Management of Patients With Pancreatic Cancer Using the "Right Track" Model.
   Rosenzweig A, Berlin J, Chari S, Kindler H, et al · · 2023 · cited 16× · PMID 37043728 · DOI 10.1093/oncolo/oyad080
4. Pancreatic ductal adenocarcinoma in the era of precision medicine.
   Zheng-Lin B, O'Reilly EM. · · 2021 · cited 9× · PMID 33637355 · DOI 10.1053/j.seminoncol.2021.01.005
5. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
   Kocher HM, BCI-STARPAC2 team, BPTB team, Precision-Panc team, et al · · 2025 · cited 6× · PMID 39833722 · DOI 10.1186/s12885-024-13333-z
6. Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients.
   Herrero Colomina J, Johnston E, Duffus K, Zaïr ZM, et al · · 2025 · cited 3× · PMID 40133697 · DOI 10.1038/s41698-025-00863-3